Human Peripheral Blood CD34+ Cells

Overview

Human Peripheral Blood CD34+ Cells is a cell model used for research applications where physiologically relevant identity and donor background support interpretation of experimental readouts. Human Immune Cells AND Hematopoietic Cells derived from Peripheral Blood (Peripheral Blood CD34+) within the Blood system.

CD34, a transmembrane glycoprotein expressed on the surface of hematopoietic progenitor cells and small blood vessel endothelial cells, is regarded as a marker of hematopoietic stem cells (HSC) and hematopoietic progenitor cells [1] . CD34+ cells have been shown to possess colony-forming potential in short-term assays, maintain long-term colony-forming potential in in vitro cultures and allow the expression and differentiation of blood cells from different hematopoietic lineages in in vivo models [2] . The CD34+ Progenitor Cells contain two main cellular subpopulations, hematopoietic and endothelial progenitor cells. Therefore, CD34+ Progenitor Cells are suitable for a series of studies, e.g. directed differentiation into more committed types of blood cells and endothelial lineages. iXCells Biotechnologies offers CD34+ Progenitor Cells from the peripheral blood of healthy donors. These cells are positively isolated using a direct immunomagnetic CD34 MicroBead labeling system. > 90% of the cells are CD34+ as showed by flow cytometric analysis of iXCells CD34+ Progenitor Cells. Figure 1 : The representative flow cytometry analysis result of Human Peripheral Blood CD34+ Cells.

Key elements and design rationale

• Cell identity: Immune Cells AND Hematopoietic Cells (Primary Cells)
• Source context: Peripheral Blood; Peripheral Blood CD34+; Blood
• Biosafety level: BSL-2 (follow your institution’s biosafety program and local regulations)

Product-specific elements (such as tissue source, donor background, and cell classification) help frame how results should be interpreted across assays and experimental conditions.

Biological background

Cells originating from the Blood system are commonly studied to understand tissue-specific physiology, signaling, and responses to perturbations in controlled in vitro settings.

Across primary and specialty cell models, experimental outcomes can be influenced by donor heterogeneity, passage history, confluence, and media composition. For interpretation, it is common to validate key markers or functional phenotypes in the user’s assay context and to document culture variables consistently.

Research relevance and current trends

• Increasing use of primary and specialty cells to improve translational relevance for target biology and phenotypic screening.
• Adoption of 3D culture formats and co-culture systems to better capture tissue microenvironments and cell–cell interactions.
• Integration of functional readouts with single-cell and multi-omics profiling to connect phenotype with molecular state.
• Expansion of high-dimensional immune phenotyping and perturbation screens to map activation states and functional programs.

Common research applications

• Profile identity markers by flow cytometry or immunostaining in cultured cells
• Stimulate immune cells and quantify activation markers and cytokine release
• Quantify functional responses to defined stimuli relevant to the model system
• Compare baseline phenotype across donors/conditions using gene expression profiling
• Perform immune profiling by multiparameter flow cytometry to resolve major subsets

Interpretation typically focuses on how a perturbation (e.g., cytokine exposure, metabolic stress, genetic manipulation, or compound treatment) shifts marker profiles or functional readouts relative to an appropriate control matched for donor and culture variables.

Notes for experimental interpretation

• Donor-to-donor heterogeneity can influence baseline phenotype and treatment response; include biological replicates when feasible.
• Passage number, confluence, and media composition can shift gene expression and functional readouts; track and report these variables consistently.
• Contamination control (including routine mycoplasma monitoring) supports reproducibility in downstream assays.
• Use appropriate negative/positive controls for the readout (e.g., unstimulated controls, pathway agonists/antagonists) to contextualize observed changes.

SKU:BHC18500040

Customization & Add-ons: Can't find the cell line you need—or require a custom cell-based solution for your project? We can help you source the best match or support custom cell line services for diverse research needs, including cell line sourcing and selection (species, tissue, and disease model matching), stable cell line engineering (overexpression, knockdown, or knockout via CRISPR/Cas9, shRNA, or sgRNA), reporter gene integration (GFP, RFP, luciferase, and other fluorescent or bioluminescent constructs), genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles), inducible expression systems (Tet-On/Off and other regulatable constructs), drug resistance marker selection (puromycin, G418, hygromycin, and others), custom growth and media optimisation for specific assay requirements, scale-up production for high-throughput screening campaigns, and authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.